510(k) Report

PMA · Approved

Approved

Thoraflex™ Hybrid

P210006PMAApproved Apr 19, 2022418-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Vascutek, Ltd. · QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment

Approved on Apr 19, 2022 through premarket approval, which rests on the device’s own clinical evidence after a 418-day review.

Decided
Apr 19, 2022
Review
418 days
Class
Class III
Product code
QSK
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P210006 has 18 supplements since 2022: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

2022: 32023: 32024: 22025: 62026: 4
2022high 6 (2025) · low 2 (2024)2026
View FIG. 1 as a table
YearSupplements approved
20223
20233
20242
20256
20264
FIG. 1 — Supplements to P210006, 2022–2026Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QSK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All QSK devices

QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · QSK

6in 2025

2022: 42023: 32024: 22025: 62026 (partial year): 5
2007high 6 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QSK

Too few QSK 510(k)s in any year since 2007 to give a median.

Recalls per year · QSK

No recall names QSK since 2007.

Adverse event reports per year · QSK

171in 2025

2022: 112023: 262024: 582025: 171
2007high 171 (2025) · low 0 (2007)2025

MAUDE reports naming product code QSK, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20224—011
20233—026
20242—058
20256—0171
20265—0—
Cite this page

510(k) Report. “P210006: Thoraflex™ Hybrid.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/P210006

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026